$ABUS news today. This is the next step we're waiting for - Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update ABUS
WARMINSTER, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its fourth quarter and year-end 2020 financial results and corporate update for Thursday, March 4, 2021. The schedule for the press release and conference call/webcast are as follows:
\-- Q4 and Year End 2020 Press Release: March 4, 2021 at 7:30 a.m. ET Q4 and Year End 2020 Conference -- Call/Webcast: March 4, 2021 at 8:45 a.m. ET -- Domestic Dial-In Number: (866) 393-1607 -- International Dial-In Number: (914) 495-8556 -- Conference ID Number: 4084504
A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at [www.arbutusbio.com](https://www.arbutusbio.com) or directly at Live Webcast.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 4084504.
About Arbutus Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit [www.arbutusbio.com](https://www.arbutusbio.com).